USC.edu
Are you a Patient?

Trevor Angell, MD

Associate Professor of Clinical Medicine

Associate Medical Director of Thyroid Center

Image of Trevor Angell, MD
Is this your profile? Click to edit
Phone +1 323 442 6179
Email tangell@usc.edu
CTSI Profile

Overview

Trevor E Angell, MD is an Associate Professor of Clinical Medicine in the Department of Medicine’s division of endocrinology and diabetes at Keck School of Medicine of USC. Dr. Angell is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interest is the diagnosis and treatment of thyroid diseases. He is recognized for clinical expertise in thyroid nodules, thyroid cancer, and thyroid disorders during pregnancy. He is nationally known for research into thyroid nodule evaluation and molecular testing of thyroid nodules.
Dr. Angell has published articles in JAMA Surgery, Thyroid, the Journal of Clinical Endocrinology and Metabolism, and Current Opinion in Endocrinology and Diabetes, including original research and invited reviews. He has received funding for his research predicting thyroid cancer in patients with thyroid nodules from the Thyroid Cancer Survivors’ Association (American Thyroid Association Research Grant). He is on the editorial board of the top endocrinology journals, including Thyroid and the Journal of Clinical Endocrinology and Metabolism. He is currently a member of the American Thyroid Association Thyroid Nodule Guidelines Taskforce and a member of the International Thyroid Oncology Group.
After finishing his clinical and research training at the Keck School of Medicine and the Los Angeles General Medical Center, Dr. Angell became an instructor in medicine at the Brigham and Women’s Hospital and Harvard Medical School, performing patient care, residents and fellow teaching, and research. Dr. Angell returned to USC and joined the faculty at the Keck School of Medicine in 2018.

Publications

  • Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci JAMA Otolaryngol Head Neck Surg. 2024 Mar 01; 150(3):209-214. . View in PubMed
  • Clinical Features and Outcomes of Myxedema Coma in Patients Hospitalized for Hypothyroidism: Analysis of the United States National Inpatient Sample Thyroid. 2024 Feb 28. . View in PubMed
  • Evaluation of YouTube As A Source For Graves’ Disease Information: Is High-Quality Guideline-Based Information Available? OTO Open. 2024 Jan-Mar; 8(1):e118.. View in PubMed
  • Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report Case Rep Ophthalmol. 2024 Jan-Dec; 15(1):115-121. . View in PubMed
  • Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis AACE Clin Case Rep. 2023 Sep-Oct; 9(5):162-165. . View in PubMed
  • Malignancy Risk of Thyroid Nodules That Are Not Classifiable by the American Thyroid Association Ultrasound Risk Stratification System: A Systematic Review and Meta-Analysis Thyroid. 2023 05; 33(5):593-602. . View in PubMed
  • Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus Front Endocrinol (Lausanne). 2023; 14:1242830. . View in PubMed
  • Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis Sci Transl Med. 2023 05 17; 15(696):eadg0675. . View in PubMed
  • Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis J Clin Endocrinol Metab. 2023 05 17; 108(6):1526-1532. . View in PubMed
  • Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves’ Disease in Patients With Active Thyrotoxicosis Endocr Pract. 2022 May; 28(5):502-508. . View in PubMed
  • Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier Thyroid. 2022 09; 32(9):1069-1076. . View in PubMed
  • Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study Clin Breast Cancer. 2022 06; 22(4):e558-e566. . View in PubMed
  • Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto’s Thyroiditis Thyroid. 2022 05; 32(5):496-504. . View in PubMed
  • Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment Front Endocrinol (Lausanne). 2022; 13:824226. . View in PubMed
  • Finding the Balance on Extent of Initial Thyroidectomy for Low-Risk Papillary Thyroid Carcinoma J Clin Endocrinol Metab. 2022 12 17; 108(1):e7-e8. . View in PubMed
  • Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy J Immunol. 2022 08 15; 209(4):696-709. . View in PubMed
  • COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study Endocr Pract. 2021 Feb; 27(2):90-94. . View in PubMed
  • Hypoglycemic episodes predict length of stay in patients with acute burns J Crit Care. 2021 08; 64:68-73. . View in PubMed
  • Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection J Med Virol. 2021 05; 93(5):2645-2653. . View in PubMed
  • Hürthle cell lesions of the thyroid: Progress made and challenges remaining Cancer Cytopathol. 2021 05; 129(5):347-362. . View in PubMed
  • Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis Oncologist. 2021 02; 26(2):e251-e260. . View in PubMed
  • Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines Ann Surg Oncol. 2021 Jan; 28(1):484-491. . View in PubMed
  • Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy Ann Transl Med. 2020 Oct; 8(19):1238. . View in PubMed
  • Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology Thyroid. 2020 09; 30(9):1390-1392. . View in PubMed
  • Insights From a Real-World Study of Molecular Test Performance for Indeterminate Thyroid Nodules J Clin Endocrinol Metab. 2020 04 01; 105(4). . View in PubMed
  • Treatment of Differentiated Thyroid Carcinomas Surg Pathol Clin. 2019 Dec; 12(4):931-942. . View in PubMed
  • Getting more out of molecular testing for indeterminate thyroid nodules Cancer Cytopathol. 2019 Sep; 127(9):555-556. . View in PubMed
  • The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer J Endocr Soc. 2019 Apr 01; 3(4):791-800. . View in PubMed
  • Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis Endocr Pathol. 2019 Mar; 30(1):43-48. . View in PubMed
  • Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules Thyroid. 2019 11; 29(11):1594-1605. . View in PubMed
  • GROWTH HAPPENS: HOW CAN INCREASING THYROID NODULE SIZE BE USED TO PREDICT MALIGNANCY? Endocr Pract. 2019 10; 25(10):1074-1076.. View in PubMed
  • Thyroid Nodules and Thyroid Cancer in the Pregnant Woman Endocrinol Metab Clin North Am. 2019 09; 48(3):557-567. . View in PubMed
  • Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults Thyroid. 2019 08; 29(8):1097-1104. . View in PubMed
  • The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders Cancer Immunol Res. 2019 07; 7(7):1214-1220. . View in PubMed
  • Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Thyroid. 2019 05; 29(5):650-656. . View in PubMed
  • Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples Front Endocrinol (Lausanne). 2019; 10:612. . View in PubMed
  • Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery Ann Surg Oncol. 2019 Jan; 26(1):93-97. . View in PubMed
  • A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules J Clin Endocrinol Metab. 2019 11 01; 104(11):5665-5672. . View in PubMed
  • POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS Endocr Pract. 2018 Jun; 24(6):512-516. . View in PubMed
  • Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule Ann Surg Oncol. 2018 May; 25(5):1410-1417. . View in PubMed
  • Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma Genes Dis. 2018 Mar; 5(1):46-48. . View in PubMed
  • Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Endocr Pathol. 2018 Mar; 29(1):68-74. . View in PubMed
  • Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers Thyroid. 2018 04; 28(4):445-453. . View in PubMed
  • Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients =70 Years Old Thyroid. 2018 04; 28(4):465-471. . View in PubMed
  • Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients Thyroid. 2018 04; 28(4):437-444. . View in PubMed
  • Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children J Clin Endocrinol Metab. 2018 09 01; 103(9):3557-3565. . View in PubMed
  • Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules JAMA Surg. 2018 09 01; 153(9):817-824. . View in PubMed
  • A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience Cancer Cytopathol. 2017 Nov; 125(11):854-864. . View in PubMed
  • RAS-positive thyroid nodules Curr Opin Endocrinol Diabetes Obes. 2017 Oct; 24(5):372-376. . View in PubMed
  • The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas Endocr Pathol. 2017 Jun; 28(2):171-176. . View in PubMed
  • Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes Cancer Cytopathol. 2017 05; 125(5):313-322. . View in PubMed
  • Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of “Carcinomas” Harboring RAS Mutations Thyroid. 2017 04; 27(4):506-511. . View in PubMed
  • Differential Growth Rates of Benign vsMalignant Thyroid Nodules. J Clin Endocrinol Metab. 2017 12 01; 102(12):4642-4647. . View in PubMed
  • Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent Thyroid. 2016 Mar; 26(3):381-9. . View in PubMed
  • Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis Thyroid. 2016 Feb; 26(2):256-61. . View in PubMed
  • Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study BMC Med. 2016 Jan 27; 14:11. . View in PubMed
  • Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma J Clin Endocrinol Metab. 2016 12; 101(12):4938-4944. . View in PubMed
  • Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier Thyroid. 2016 07; 26(7):911-5. . View in PubMed
  • HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS AACE Clin Case Rep. 2016; 2(4):e370-e373. . View in PubMed
  • The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk J Clin Endocrinol Metab. 2015 Dec; 100(12):4434-40. . View in PubMed
  • Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up J Clin Endocrinol Metab. 2015 Nov; 100(11):E1477-83. . View in PubMed
  • Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge Ann Hematol. 2015 Sep; 94(9):1603-4. . View in PubMed
  • The variable phenotype and low-risk nature of RAS-positive thyroid nodules BMC Med. 2015 Aug 07; 13:184. . View in PubMed
  • Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. . View in PubMed
  • MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. . View in PubMed
  • BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration Thyroid. 2014 Sep; 24(9):1385-93. . View in PubMed
  • In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation Thyroid. 2014 Jul; 24(7):1127-33. . View in PubMed

Similar People